FIGURE 8.
Impact of antibodies to serpin B13 on IDAA1C in recent-onset T1D patients. Fifty-four placebo subjects previously recruited to Type 1 Diabetes TrialNet protocols were examined for baseline secretion of serpin B13 antibodies and analyzed for IDAA1C at baseline and follow-up at 3, 6, and 12 months. The negative samples were compared with samples that showed weak (+) (A) or strong (++) (B) binding to serpin B13. Linear regression was used for the analysis. Data are presented as mean ± S.E.